



10 626 213

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Barbera-Guillem et al.	Examiner:	Not Assigned Yet
Application No.:	Not Yet Assigned	Group Art:	Not Assigned Yet
Filing Date:	July 24, 2003	Docket No.:	26983-133
Title:	Methods and Compositions for Immunotherapy of B Cell Involvement in Promotion of a Disease Condition Comprising Multiple Sclerosis		

Mail Stop- DD  
Commissioner for Patents  
P.O. Box. 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Examiner:

1. This Information Disclosure Statement is filed in accordance with 36 C.F.R. §§§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

2. Pursuant to 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

3. Pursuant to 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed as an admission that the information cited in this Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

4. Regarding each listed document that is not in the English language, an English-language translation accompanies this Statement as indicated on the attached PTO-1449 or a concise explanation of the relevance of the document is set forth in the following document(s):

- ☐ Copy of each English language version of a search report by a foreign patent office in a counterpart foreign application, indicating the degree of relevance found by the foreign office of each document being submitted from the search report.
- ☐ Attached abstract for Non-English Language Documents.

5. Pursuant to 37 C.F.R. § 1.97(b) this Statement is being filed:

- ☐ within 3 months of the filing date of a national application; or
- ☐ within 3 months of the date of the entry of the national stage as set forth in 37 CFR § 1.491 in an international application; or
- ☒ before the mailing date of a first Office Action on the merits.

An Information Disclosure Statement along with copies of the references were submitted in the parent application, U.S. Serial No. 09/643,595, filed August 22, 2000, therefore copies of the references are not being resubmitted. If the Examiner wishes to receive additional copies of the references, notification of such is requested.

The Commissioner is hereby authorized to charge any additional fees required for consideration of this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 02-2051, identifying our Docket No. 26983-133.



Dated: 7/25/03

Respectfully submitted,

BENESCH, FRIEDLANDER  
COPLAN & ARONOFF LLP

A handwritten signature in black ink, appearing to read "N. Nicole Endejann", written over a horizontal line.

N. Nicole Endejann  
Reg. No. 50,229  
2300 BP Tower  
200 Public Square  
Cleveland, OH 44114-2378  
(216) 363-4443



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Unknown 10 626 215		
		Filing Date	07/24/2003		
		First Named Inventor	Barbera-Guillem et al.		
		Group Art Unit	Unknown		
		Examiner Name	Unknown		
Sheet	2	of	2	Attorney Docket Number	26983-133

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BA	Barbera-Guillem et al., 1999, Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies, Neoplasia, 1:453-460.	
	BB	Barbera-Guillem et al., 2000, B Lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion, Cancer Immunology and Immunotherapy, 48:541-549.	
	BC		
	BD		
	BE		
	BF		
	BG		
	BH		
	BI		
	BJ		
	BK		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.